Biovaxys And The Ohio State University Enter Into SARS-CoV-2 Research Collaboration To Study New Vaccine

October 26,     2020      Vancouver, British Columbia  BioVaxys Technology Corp. (CSE: BIOV), is pleased to announce that it has entered into a research collaboration with The Ohio State University (“OSU”) for BioVaxys’ SARS-CoV-2 vaccine candidate. OSU is a leading global academic research institute in the fight against SARS-CoV-2, with The Ohio State University Wexner Medical Center […]

Appointment of New Director

October 16, 2020 – Vancouver, British Columbia – BioVaxys Technology Corp. (formerly Lions Bay Mining Corp.) (“BioVaxys” or the “Company”) (CSE: BIOV) is pleased to announce that David Wang and Darren Hermiston have been appointed as directors of the Company. Mr. Hermiston replaces Timothy Heenan, who has resigned to pursue other endeavors. The Company would […]

BioVaxys Announces Interim Results From Preclinical Study of its SARS-CoV-2 Vaccine

October  14th, 2020  Vancouver, British Columbia BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys”) is pleased to announce that interim results from its ongoing preclinical animal study (also known as a “murine model study”) of BXV-0320, its SARS-CoV-2 vaccine candidate, show a good emerging tolerability profile with no observed side effects or noteworthy clinical observations.  Five weeks […]

Lions Bay Announces Closing Of Final Tranche Of Non-brokered Private Placement And Provides Update On Completion Of Production And Start Of Dosing In Biovaxys’ Preclincal Study Of SARS-CoV-2 Vaccine

September 4, 2020 Vancouver, British Columbia – Lions Bay Mining Corp. (“Lions Bay” or the “Company”) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the “Private Placement”). Under the final tranche (the “Final Tranche”) of the Private Placement, the Company issued 2,954,582 units […]

Lions Bay Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing

Lions Bay Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing Vancouver, British Columbia–(Newsfile Corp. – June 4, 2020) – Lions Bay Mining Corp. (CSE: LBM) (the “Company” or “Lions Bay”) is pleased to announce that it has executed a Share Exchange Agreement (the “Definitive Agreement”) with BioVaxys Inc. (previously known as BioVaxys LLC) (“BioVaxys”), […]

Lions Bay Mining Announces Update on Acquisition Target BioVaxys Initiating A SARS-CoV-2 Vaccine Study

Vancouver, British Columbia–(Newsfile Corp. – May 14, 2020) – Lions Bay Mining Corp. (CSE: LBM) (the “Company” or “Lions Bay“) is pleased to announce that it has been informed that BioVaxys LLC ( “BioVaxys”) is in the process of preparing to launch a preclinical study of its proprietary vaccine for SARS-CoV-2, the virus that causes […]

Thomas Jefferson University and BioVaxys LLC enter into exclusive worldwide license

PHILADELPHIA–(BUSINESS WIRE)–Thomas Jefferson University, a Philadelphia-based professional university with a national reputation for transdisciplinary learning and innovation, and BioVaxys LLC, a privately-held, clinical stage biotechnology company, announced today that they have entered into an exclusive worldwide license agreement for a technology comprising highly-targeted, patient-specific, immunotherapeutic vaccines to treat ovarian cancer, melanoma, and other solid tumor […]